Diabetes News Chronicle


Diabetes, Cardiovascular And Heart Diseases - 204

 

Published on June 14, 2017 at 04:30 AM GMT

True Cause Of Respiratory Weakness Or Dyspneas In Heart Failure
True Cause Of Respiratory Weakness Or Dyspneas In Heart Failure A study done by researchers from the University of Guelph, Guelph, Ontario, Canada and the Dalhousie University, Halifax, Nova Scotia, Canada shows brain is the true cause of respiratory weakness or dyspneas in heart failure. Researchers conducted six years of painstaking experiments and studies with mice models to find out respiratory weakness mechanism contributing to dyspnea in heart failure. The experiments led to discovery of a diaphragm (a large muscle) which helps in the breathing function. Faulty signals from brain causes problems to the functioning of this diaphragm. That shows brain functionality is the root cause of the respiratory weakness or dyspneas. Under certain conditions, breathing problems in mice models were prevented by using a first line heart therapy medications and blood pressure controlling medications.

Co-author of the study was Keith Brunt, assistant professor of pharmacology, Dalhousie Medical School, Dalhousie University, Saint John, Canada and lead author of the study was Jeremy Simpson, professor of human health and nutritional sciences, University of Guelph, Guelph, Ontario, Canada. The study findings were published May, 2017 in the journal Science Translational Medicine. This study was funded by

Articles related to   Heart Diseases

 

US FDA Adds Boxed Amputation Risk Warning To Invokana Type 2 Diabetes Drug
US FDA Adds Boxed Amputation Risk Warning To Invokana Type 2 Diabetes Drug The United States Food and Drug Administration (FDA) said that a new boxed warning to amputation must be added to the label of invokana (canagliflozin) drug, a type 2 diabetes (T2D) medication manufactured by Janssen Pharmaceuticals. Boxed warning means possibilities of the most serious adverse events. Results of two large clinical trials (CANVAS and CANVAS-R) on the performance of invokana type 2 diabetes (T2D) drug shows increased risk to amputations of leg and foot when compared to placebo drug. The United States Food and Drug Administration (FDA) has requested healthcare professionals and patients using invokana medication to give feedback on the side effects. The FDA received following leg amputations reports with the usage of invokana medication.

Articles related to   Fda   |   Amputation   |   Health Risks   |   Invokana   |   Drug

 

Metformin Improves Health Outcomes In HER2 And Breast Cancer Patients With Diabetes
Metformin Improves Health Outcomes In HER2 And Breast Cancer Patients With Diabetes Researchers says health forecast of breast cancer patients with diabetes were poor when compared with non-diabetic patients. An analysis of the phase III ALTTO trial done by the researchers at Jules Bordet Institute shows health improvements in diabetic patients with HER2 (human epidermal growth factor receptor 2) and positive primary breast cancer with the usage of metformin drug. Researchers observed direct and indirect anti-tumor effects, particularly in breast cancer patients with the usage of metformin drug during the analysis of pre-clinical and clinical data. The researchers conducted analytical studies among 8,381 patients. Diabetic patients under metformin treatment were 186 and without metformin treatment were 260. The results after a 4.5 years of follow up studies shows

Significant worse disease-free survival (DFS) events were found in those diabetic patients who were not treated with metformin when compared with non-diabetic patients. Similar health outcomes were found in diabetic patients under the treatment of metformin and non-diabetic patients. Even though there is no level 1 evidence, the researchers says health care professionals may recommend metformin treatment to avoid possible insulin usage in those patients with HER2-positive and hormone receptor positive disease and diabetes. Those patients used insulin may be at higher risk of recurrence. Lead author of the study was Evandro de Azambuja, MD, PhD from the Jules Bordet Institute, Brussels and the study findings were published in the Journal of Clinical Oncology.

Articles related to   Metformin   |   Cancer

 

 

Categories

Sitemap 1

Sitemap 2

Sitemap 3

Articles related to Acids Page 1  

Articles related to Approval Page 1  

Articles related to Apps Page 1   Page 2  

Articles related to Blood Sugar Levels Page 1  

Articles related to Blood-pressure Page 1  

Articles related to Cancer Page 1  

Articles related to Cardiovascular Diseases Page 1  

Articles related to Children Page 1  

Articles related to Cholesterol Page 1  

Articles related to Dementia Page 1  

Articles related to Dental Problems Page 1  

Articles related to Depression Page 1  

Articles related to Drugs Page 1   Page 2  

Articles related to Eldercare Page 1  

Articles related to Gut Microbiomes Page 1  

Articles related to Health Benefits Page 1   Page 2  

Articles related to Health Biomarkers Page 1  

Articles related to Health Risks Page 1   Page 2   Page 3   Page 4   Page 5  

Articles related to Health Supplements Page 1   Page 2  

Articles related to Heart Diseases Page 1   Page 2   Page 3  

Articles related to Hormones Page 1  

Articles related to Insulin Page 1   Page 2  

Articles related to Kidney Page 1  

Articles related to Liver Diseases Page 1  

Articles related to Metformin Page 1  

Articles related to Miscellaneous Page 1  

Articles related to Neuropathy Page 1  

Articles related to Obesity Page 1  

Articles related to Physical Activity Page 1  

Articles related to Pollution Page 1  

Articles related to Precautions Page 1  

Articles related to Retinopathy Page 1  

Articles related to Sleeping Disorders Page 1  

Articles related to Stroke Page 1  

Articles related to Therapy Page 1  

Articles related to Weight Loss Surgery Page 1  

Articles related to Women Health Page 1   Page 2  

 

Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.